Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

52 results about "Biapenem" patented technology

Biapenem (INN) is a carbapenem antibiotic. It has in vitro activity against anaerobes. 1-β-methyl-carbapenem antibiotic. Approved in Japan in 2001.

Crystal form of 6, 7-dihydro-6-mercapto-5H-pyrazolo[1,2-alpha][1,2,4] triazoliumchloride and preparation method thereof

The invention relates to a crystal form of 6, 7-dihydro-6-mercapto-5H-pyrazolo [1,2-alpha][1,2,4] triazoliumchloride and a preparation method thereof. The 6, 7-dihydro-6-mercapto-5H-pyrazolo [1,2-alpha][1,2,4] triazoliumchloride is a key intermediate for synthesizing the carbapenem antibiotic biapenem. The crystal form of 6,7-dihydro-6-mercapto-5H-pyrazolo[1,2-alpha][1,2,4] triazoliumchloride is characterized in that the X-ray diffraction spectrum of powder of the crystal form is represented by an angle of 2theta, and has peaks at 27.487+ / -0.2 and 26.707+ / -0.2, the intensity of the peak is 100% when 2theta is 27.487+ / -0.2, and the ratio of intensity of the peak I / I0 is no less than 60% when 2theta is 26.707+ / -0.2. The 6, 7-dihydro-6-mercapto-5H-pyrazolo[1,2-alpha][1,2,4] triazoliumchloride is prepared by the recrystallization method which abandons the column chromatography and has high efficiency and low cost and is more suitable for industrialized production.
Owner:石药集团中诺药业(石家庄)有限公司 +1

Method for preparing biapenem

The invention discloses a method for preparing biapenem, which is applicable to industrialization. The method comprises the following steps: performing a hydrogenation reaction on aprotic polar organic solvent serving as the solvent for a catalytic hydrogenation reaction and H2 in the presence of a catalyst; removing the protective group of a compound in a formula (II); and collecting the biapenem in reaction mixture. By using the method, the usage amount of reaction solvent is small, and the production capability of a pressure reaction still is greatly improved. Moreover, the reaction condition is mild; the operation is simple; and the biapenem can directly be precipitated from water and the organic solvent by using the solubility of the product without buffer, purification of ion exchange resin, concentration of mass aqueous solution or low temperature freezing crystallization, so that the separation and purification operation processes of the product are simplified, and the reaction yield is improved; and the obtained product has high purity, and the method is applicable to industrial and large-scale production.
Owner:SICHUAN KELUN PHARMA CO LTD

Biapenem crystalline compound and composition powder-needle thereof

The invention relates to a biapenem crystalline compound, which is measured by using a powder X-ray diffraction measurement method. An X-ray powder diffraction pattern indicated by a diffraction angle of 2 theta + / -0.2 degree shows feature diffraction peak at the positions of 5.9 degrees, 6.5 degrees, 10.5 degrees, 14.8 degrees, 15.6 degrees, 16.3 degrees, 17.4 degrees, 19.8 degrees, 22.9 degrees, 23.7 degrees, 25.1 degrees, 28.4 degrees and 34.7 degrees. The invention further relates to a biapenem composition powder-needle comprising the biapenem crystalline compound. Components of the composition powder-needle are 95 to 100 parts of the biapenem crystalline compound and 0.1 to 1 part of sodium benzoate.
Owner:SHANDONG LUOXIN PARMACEUTICAL GROUP STOCK CO LTD +2

Biapenem composition freeze-dried powder for injection

The invention provides a biapenem composition freeze-dried powder for injection, and belongs to the field of medicine and medicine preparation technology. The biapenem composition freeze-dried powder comprises following raw material ingredients, by weight, 1 part of biapenem, 0.2 to 10 parts of chitosan nanoparticle, and 91.18 to 93.08 parts of injection water. Advantages of the biapenem composition freeze-dried powder are that: the chitosan nanoparticle is used as a freeze-dried skeleton agent of the freeze-dried powder injection instead of mannitol, so that active effects of mannitol on human bodies are avoided, problems of stability and solubility are solved at the same time, antibacterial effect of biapenem is improved significantly, dosage of biapenem in clinic is reduced, and adverse reaction of biapenem is reduced. The biapenem composition freeze-dried powder is successfully developed, and is capable of providing novel ideas for clinical application of biapenem.
Owner:HAINAN WEI KANG PHARMA QIANSHAN

Preparation method of biapenem

The invention discloses a preparation method of biapenem. The preparation method comprises the following steps: (a) by using a compound shown in a formula III as a raw material, adding a palladium catalytic system with the weight ratio of triphenyl phosphine and tri(triphenyl phosphine) palladium of (1-3) to 1 into an organic solvent, and stirring to reaction for 1.5-2 hours at 10-50 DEG C, wherein the addition of tri(triphenyl phosphine) palladium is 1.5-2% of formula III; (b) adding water into a reaction liquid in the step (a) to dilute, washing by dichloroethane or dichloromethane, and decompressing and concentrating to obtain an aqueous solution, wherein the water phase contains biapenem; and (c) adjusting the pH of the biapenem aqueous solution obtained in the step (b) to 5-6 by an organic solvent, adding acetone or ethanol, cooling to below room temperature, stirring and carrying out crystallization for 2-3 hours to separate out biapenem crystals. In the reaction process, hydrogen is not used, and the reaction does not generate hydrogen too. The reaction condition is mild, and the production safety is greatly improved. In the reaction, buffer salt needs not to be added to control the pH of the reaction liquid, so that the preparation method is suitable for industrialized production and simple to operate.
Owner:SHANGHAI NEW ASIA PHARMA +1

Application of biapenem in preparation of medicine for preventing and treating bovine enterovirus infection

The invention provides an application of biapenem in preparation of a medicine for preventing and treating bovine enterovirus infection. The compound biapenem can effectively inhibit proliferation ofbovine enterovirus and has low toxicity to cells, and experiments prove that the median toxicity concentration (CC50) of biapenem to MDBK cells is greater than 100 [mu]M, and the median effective concentration (EC50) of biapenem to bovine enterovirus is 60 [mu]M; the treatment index of biapenem to bovine enterovirus is greater than 1.67, which indicates that biapenem has a prospect of being developed into a drug for preventing and / or treating bovine enterovirus infection, opens up the new drug application for biapenem, lays an experimental foundation for developing efficient and specific anti-BEV drugs, and provides a new visual field.
Owner:DAIRY CATTLE RES CENT SHANDONG ACADEMY OF AGRI SCI +1

Refining method of biapenem crude product

The invention belongs to the technical field of chemical pharmacy, and particularly relates to a refining method of a biapenem crude product. According to the invention, a biapenem refining process is optimized, and crystallization is carried out by stages under different temperature conditions by adopting a reverse crystallization mode of dropwise adding a feed liquid into a crystallization agent. The temperature of first crystallization is-10 to 10 DEG C, crystallization is carried out at a low temperature, crystals can be rapidly separated out, the form of the crystals is easy to control, and the granularity of the crystals of the obtained product is small; the temperature of secondary crystallization is 5-30 DEG C, and crystallization is carried out at a relatively high temperature, so that solvent residues of the product can be reduced. The product prepared by the method disclosed by the invention is short in redissolution time, high in purity, high in yield and good in stability, the crystal form of the product is consistent with that of an original product, and a powerful guarantee is provided for product consistency evaluation.
Owner:ZHUHAI UNITED LAB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products